+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gene Therapy in CVMD

  • PDF Icon


  • 80 Pages
  • June 2018
  • Region: Global
  • GlobalData
  • ID: 4601487
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Gene Therapy in CVMD


Gene therapies have been a point of discussion during the last several years as a potential curative option for a variety of disease indications. While mainly still in preclinical stages, gene therapy aims to treat or alleviate a disease by genetically modifying the cells of a patient. This report focuses on gene therapies in development across the 8MM for cardiovascular and metabolic disorders, including coronary artery disease, critical limb ischemia, diabetic foot ulcers, and Pompe Disease. In addition, this report provides an assessment of the pipeline, clinical, and commercial landscape of gene therapies in CVMD supplemented with a variety of KOL and payer perspectives.


This report combines KOL and Payer insights along with data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include:
  • Overview of CVMD and Gene Therapies: epidemiology and regulatory oversight

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors

  • Market Access: considerations for reimbursement, pricing, and unmet needs

  • Market Outlook: competitive assessment and key market events (2018-2025).

Reasons to buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the global CVMD gene therapy market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CVMD gene therapy market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface
1.1 Related Reports
1.2 Upcoming Related Reports
1.3 Abbreviations
2. Executive Summary
2.1 Key Findings
2.2 KOL and Payer Insight on CVMD Gene Therapy Competitive Landscape
3. Overview of CVMD Gene Therapy
3.1 What is Gene Therapy?
3.2 Gene Transfer Methods and Vectors Used for Gene Therapy
3.3 Viral Vectors vs. Non Viral Vectors
3.4 Therapeutic Gene Therapy Strategies Employed in CVMD
3.5 Gene Therapy in the 8MM
4. Epidemiology Analysis
4.1 Coronary Artery Disease
4.2 Peripheral Artery Disease
4.3 Peripheral Artery Disease with Critical Limb Ischemia
4.4 Systolic Heart Failure
4.5 Diabetic Foot Ulcers
4.6 Diabetic Neuropathy
4.7 Pompe Disease
5. Pipeline Assessment
5.1 CVMD Gene Therapy Pipeline in the 8MM
5.2 Pipeline Products - Phase III
5.3 AnGes MG’s Collategene
5.4 Angionetics’ Generx
5.5 ViroMed’s Donaperminogene Seltoplasmid
5.6 Renova’s RT-100
5.7 Pipeline Products - Phase II
5.8 ID Pharma’s DVC-10101
5.9 Juventas’ JVS-100
5.10 UF’s Gene Therapy to Activate Acid Alpha Glucosidase for Pompe Disease
6. Clinical Trials Mapping and Design
6.1 Clinical Trial Mapping
6.2 Clinical Trial Design
7. Pricing and Reimbursement Strategies - Payer Perspective
7.1 Current CVMD Space
7.2 Challenges Associated with Reimbursement of Novel CVMD Therapies
7.3 Prospective Payer Strategies for CVMD Gene Therapies
8. Market Outlook
8.1 Phase III CVMD Gene Therapy Pipeline
8.2 Key Launch Dates for Phase II and III CVMD Gene Therapy Pipeline
9. Appendix
9.1 Sources
9.1 Methodology
9.2 Primary Research
9.3 About the Authors
9.4 About
9.5 Contact
9.6 Disclaimer

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AnGes MG
  • Angionetics
  • Ark Therapeutics
  • Human Stem Cells Institute
  • ID Pharma Co
  • Juventas Therapeutics
  • Renova Therapeutics
  • ViroMed Co
  • YiChang Humanwell Pharmaceutical